AP
GSK icon

Advisors Preferred’s GSK GSK Stock Holding History

Advisors Preferred’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,699
Closed -$471K – 221
2024
Q3 		$471K Buy
+11,699
New +$479K 0.07% 133
2024
Q2 		– Sell
-13,456
Closed -$428K – 185
2024
Q1 		$428K Buy
13,456
+7,608
+130% +$314K 0.07% 72
2023
Q4 		$219K Buy
+5,848
New +$210K 0.04% 132
2020
Q1 		– Sell
-1,779
Closed -$105K – 180
2019
Q4 		$105K Buy
+1,779
New +$99K 0.03% 147
2017
Q3 		– Sell
-2,592
Closed -$140K – 240
2017
Q2 		$140K Sell
2,592
-67
-3% -$3.57K 0.08% 90
2017
Q1 		$140 Buy
+2,659
New +$135K 0.07% 97
2014
Q3 		– Sell
-404
Closed -$27K – 271
2014
Q2 		$27K Sell
404
-345
-46% -$23.4K 0.01% 205
2014
Q1 		$50K Buy
+749
New +$50.6K 0.02% 266

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Advisors Preferred's GSK Position: Q4 2024 in Review

Advisors Preferred sold out of GSK (GSK) in Q4 2024, closing a stake of 11,699 shares — an estimated $471K sold.

Advisors Preferred first reported a position in GSK in Q1 2014 and held it in 8 quarters. The position peaked at $471K in Q3 2024. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

  • Advisors Preferred reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
  • Advisors Preferred sold 11,699 GSK shares in Q4 2024, an estimated $471K.
  • Advisors Preferred first reported a position in GSK in Q1 2014 and held it in 8 quarters.
  • Advisors Preferred's GSK position peaked at $471K in Q3 2024.
  • 848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on Advisors Preferred's 13F filing for Q4 2024, filed 28 Jan 2025.